Search
forLearn
5 / 801 resultslearn TDM-105795
learn HT-B
learn Trichogen
learn PTT-6®
Research
5 / 43 results
research Characterization and Management of Androgenetic Alopecia in Transgender and Gender-Diverse Individuals: A Narrative Review
Personalized hair loss treatments are needed for transgender individuals, but more research is required.
research Dermatological care of gender‐diverse patients in Australia
Australia needs better dermatological guidelines for gender-diverse patients.
research Stimulation of hair growth by Tianma Gouteng decoction: Identifying mechanisms based on chemical analysis, systems biology approach, and experimental evaluation
Tianma Gouteng decoction may help prevent hair loss and promote hair growth.
research Androgenetic Alopecia Incidence in Transgender and Gender Diverse Populations: A Retrospective Comparative Cohort Study
Transgender patients on masculinizing hormones have higher hair loss rates than cisgender women.
research Dermatological considerations for transgender and gender diverse patients: An Australian perspective
Dermatologists are essential in helping transgender and gender diverse patients with skin and hair issues related to gender affirmation and hormone therapy.
Community Join
5 / 1000+ resultscommunity PTD-DBM Update: Q&A With Dr. Kang-Yell Choi
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community Peptide Therapy -> GHK-CU, ZN-Thumulin, PTD-DBM
The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.
community TresslessGPT is now available for free
Tressless GPT is now free and accessible for hair loss advice. Treatments discussed include Minoxidil, finasteride, RU58841, dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.